Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of the International AIDS Society
Published in: Journal of the International AIDS Society 4/2010

Open Access 01-12-2010 | Poster presentation

Salvage therapy with raltegravir in a 3-month-old infant

Authors: AB Brolund, C Ilchmann, R Ganschow, O Degen

Published in: Journal of the International AIDS Society | Special Issue 4/2010

Login to get access

Excerpt

The integrase inhibitor raltegravir (RAL) is widely used in adults. Only limited data are available for children and no data for infants. We describe the case of a three-month-old infant treated with RAL in combination with lopinavir/r (LPV/r) and lamivudine (3TC). …
Metadata
Title
Salvage therapy with raltegravir in a 3-month-old infant
Authors
AB Brolund
C Ilchmann
R Ganschow
O Degen
Publication date
01-12-2010
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1758-2652-13-S4-P157

Other articles of this Special Issue 4/2010

Journal of the International AIDS Society 4/2010 Go to the issue

Oral presentation

O212. Ritonavir-boosted protease inhibitor monotherapy is 6% less effective than combination antiretroviral therapy in a meta-analysis

Poster presentation

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study

Poster presentation

The association between metabolic syndrome and the occurrence of nephrolithiasis in HIV-infected patients

Oral presentation

Early mortality following ART initiation in HIV-infected adults and children in Uganda and Zimbabwe

Oral presentation

Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile

Poster presentation

Immunologic impact of maraviroc in clinical practice of a university hospital
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits